Table 1 Patient characteristics.
From: Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer
Women | Men | |||||
|---|---|---|---|---|---|---|
HER2-zero N = 101 918 | HER2-low N = 101 324 | HER2-positive N = 36 285 | HER2-zero N = 819 | HER2-low N = 940 | HER2-positive N = 224 | |
Age at diagnosis: median years (SD) | 63.4 (13.6) | 63.3 (13.5) | 60.4 (14.1) | 68.8 (11.4) | 68.1 (11.3) | 65.6 (12.7) |
Hormone receptor status | ||||||
Positive | 77 561 (85%) | 83 514 (91%) | 22 636 (71%) | 726 (97%) | 850 (98%) | 189 (95%) |
Negative | 14 092 (15%) | 8 457 (9.2%) | 9 439 (29%) | 21 (2.9%) | 14 (1.6%) | 10 (5%) |
Missing | 10 265 | 9 353 | 4 210 | 72 | 76 | 25 |
TNM-T | ||||||
T1 | 30 954 (50%) | 34 955 (51%) | 9 172 (39%) | 160 (34%) | 228 (37%) | 37 (26%) |
T2 | 23 307 (37%) | 25 069 (36%) | 10 144 (43%) | 204 (43%) | 258 (42%) | 61 (43%) |
T3 | 3 588 (5.7%) | 3 593 (5.2%) | 1 584 (6.7%) | 8 (1.7%) | 17 (2.8%) | 8 (5.6%) |
T4 | 4 650 (7.4%) | 5 105 (7.4%) | 2 882 (12%) | 100 (21%) | 109 (18%) | 37 (26%) |
Missing | 39 419 | 32 602 | 12 503 | 347 | 328 | 81 |
TNM-N | ||||||
N0 | 41 094 (68%) | 44 502 (66%) | 12 386 (53%) | 268 (58%) | 315 (53%) | 73 (53%) |
N+ | 19 782 (32%) | 22 519 (34%) | 11 041 (47%) | 192 (42%) | 276 (47%) | 64 (47%) |
Missing | 41 7042 | 34 303 | 12 858 | 359 | 349 | 81 |
TNM-M | ||||||
M0 | 59 924 (92%) | 65 433 (92%) | 21 886 (87%) | 453 (90%) | 556 (86%) | 119 (80%) |
M1 | 5 522 (8.4%) | 5 742 (8.1%) | 3 138 (13%) | 52 (10%) | 91 (14%) | 29 (20%) |
Missing | 36 472 | 30 149 | 11 261 | 314 | 293 | 76 |
Topography code (ICD-O-3) | ||||||
500 | 748 (0.7%) | 773 (0.8%) | 462 (1.3%) | 66 (8.1%) | 82 (8.7%) | 15 (6.7%) |
501 | 5 049 (5.0%) | 5 099 (5.0%) | 1 932 (5.3%) | 252 (31%) | 333 (35%) | 69 (31%) |
502 | 11 296 (11%) | 11 664 (12%) | 3 436 (9.5%) | 26 (3.2%) | 28 (3.0%) | 5 (2.2%) |
503 | 6 141 (6.0%) | 6 343 (6.3%) | 2 119 (5.8%) | 7 (0.9%) | 16 (1.7%) | < 5 |
504 | 38 113 (37%) | 39 073 (39%) | 12 561 (35%) | 67 (8.2%) | 109 (12%) | 26 (12%) |
505 | 9 479 (9.3%) | 10 443 (10%) | 3 419 (9.4%) | 32 (3.9%) | 26 (2.8%) | 6 (2.7%) |
506 | 280 (0.3%) | 233 (0.2%) | 96 (0.3%) | 0 | 0 | < 5 |
508 | 15 385 (15%) | 15 434 (15%) | 6 140 (17%) | 85 (10%) | 102 (12%) | 38 (17%) |
509 | 15 427 (15%) | 12 262 (12%) | 6 120 (17%) | 284 (35%) | 244 (26%) | 62 (28%) |
Grade | ||||||
1 (well differentiated) | 16 003 (16%) | 16 317 (16%) | 1 380 (4.0%) | 98 (12%) | 91 (9.8%) | 13 (6.0%) |
2 (moderately differentiated) | 56 811 (57%) | 58 587 (59%) | 16 130 (46%) | 507 (64%) | 576 (62%) | 110 (51%) |
3 (poorly differentiated) | 26 293 (27%) | 24 242 (24%) | 17 318 (50%) | 190 (24%) | 257 (28%) | 93 (43%) |
Missing | 2 811 | 2 178 | 1 457 | 24 | 16 | 8 |
Registry Source | ||||||
1 | 393 (0.4%) | 247 (0.2%) | 100 (0.3%) | < 5 | < 5 | 0 |
2 | 465 (0.5%) | 391 (0.4%) | 212 (0.6%) | 5 (0.6%) | < 5 | 0 |
3 | 1 015 (1.0%) | 1 547 (1.5%) | 419 (1.2%) | 6 (0.7%) | 11 (1.2%) | < 5 |
4 | 1 787 (1.8%) | 2 030 (2.0%) | 669 (1.8%) | 13 (1.6%) | 21 (2.2%) | < 5 |
5 | 1 565 (1.5%) | 1 981 (2.0%) | 776 (2.1%) | 13 (1.6%) | 16 (1.7%) | 10 (4.5%) |
6 | 1 535 (1.5%) | 2 252 (2.2%) | 850 (2.3%) | 11 (1.3%) | 13 (1.4%) | 7 (3.1%) |
7 | 2 014 (2.0%) | 4 162 (4.1%) | 1 058 (2.9%) | 12 (1.5%) | 36 (3.8%) | 4 (1.8%) |
8 | 2 966 (2.9%) | 2 379 (2.3%) | 860 (2.4%) | 19 (2.3%) | 25 (2.7%) | < 5 |
9 | 3 059 (3.0%) | 2 653 (2.6%) | 1 148 (3.2%) | 21 (2.6%) | 17 (1.8%) | 6 (2.7%) |
10 | 6 127 (6.0%) | 6 110 (6.0%) | 1 984 (5.5%) | 38 (4.6%) | 60 (6.4%) | 15 (6.7%) |
11 | 8 555 (8.4%) | 8 126 (8.0%) | 3 002 (8.3%) | 87 (11%) | 88 (9.4%) | 20 (8.9%) |
12 | 22 036 (22%) | 24 958 (25%) | 8 281 (23%) | 195 (24%) | 219 (23%) | 61 (27%) |
13 | 50 401 (49%) | 44 488 (44%) | 16 926 (47%) | 396 (48%) | 429 (46%) | 95 (42%) |
Histology | ||||||
Ductal | 75 387 (74%) | 79 321 (78%) | 31 694(87%) | 725 (89%) | 856 (91%) | 207 (92%) |
Lobular | 18 300 (18%) | 16 377 (16%) | 2 707 (7.5%) | 39 (4.8%) | 39 (4.1%) | < 5 |
Other | 8 231 (8.1%) | 5 626 (5.6%) | 1 885 (5.2%) | 55 (6.7%) | 45 (4.8%) | 13 (5.8%) |
